MBIO vs. NEXI, EVOK, CING, VRPX, BPTS, PHAS, GOVX, KTRA, ARDS, and THAR
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include NexImmune (NEXI), Evoke Pharma (EVOK), Cingulate (CING), Virpax Pharmaceuticals (VRPX), Biophytis (BPTS), PhaseBio Pharmaceuticals (PHAS), GeoVax Labs (GOVX), Kintara Therapeutics (KTRA), Aridis Pharmaceuticals (ARDS), and Tharimmune (THAR). These companies are all part of the "pharmaceutical preparations" industry.
NexImmune (NASDAQ:NEXI) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, community ranking, analyst recommendations, institutional ownership, media sentiment and dividends.
NexImmune is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Mustang Bio received 146 more outperform votes than NexImmune when rated by MarketBeat users. Likewise, 64.12% of users gave Mustang Bio an outperform vote while only 61.11% of users gave NexImmune an outperform vote.
In the previous week, Mustang Bio had 1 more articles in the media than NexImmune. MarketBeat recorded 2 mentions for Mustang Bio and 1 mentions for NexImmune. NexImmune's average media sentiment score of 0.86 beat Mustang Bio's score of 0.50 indicating that Mustang Bio is being referred to more favorably in the news media.
9.9% of NexImmune shares are owned by institutional investors. Comparatively, 10.0% of Mustang Bio shares are owned by institutional investors. 19.4% of NexImmune shares are owned by company insiders. Comparatively, 2.1% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
NexImmune has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500.
Mustang Bio's return on equity of -247.17% beat NexImmune's return on equity.
Mustang Bio has a consensus target price of $17.25, suggesting a potential upside of 4,828.57%. Given NexImmune's higher possible upside, analysts plainly believe Mustang Bio is more favorable than NexImmune.
Summary
Mustang Bio beats NexImmune on 10 of the 14 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
